Advances and Challenges of Liposome Assisted Drug Delivery

Allen, 1994, Long-circulating (sterically stabilized) liposomes for targeted drug delivery, Trends Pharmacol. Sci., 15, 215, 10.1016/0165-6147(94)90314-X

Allen, 2004, Drug delivery systems: entering the mainstream, Science, 303, 1818, 10.1126/science.1095833

Allen, 2013, Liposomal drug delivery systems: from concept to clinical applications, Adv. Drug Deliv. Rev, 65, 36, 10.1016/j.addr.2012.09.037

Andresen, 2004, Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs, J. Med. Chem., 47, 1694, 10.1021/jm031029r

Antohe, 2004, Transendothelial movement of liposomes in vitro mediated by cancer cells, neutrophils or histamine, J. Liposome Res., 14, 1, 10.1081/LPR-120039660

Antoni, 2014, Intestinal barrier in inflammatory bowel disease, World J. Gastroenterol., 20, 1165, 10.3748/wjg.v20.i5.1165

Awada, 2014, A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC), Ann. Oncol., 25, 824, 10.1093/annonc/mdu025

Bendas, 2001, Immunoliposomes: a promising approach to targeting cancer therapy, BioDrugs, 15, 215, 10.2165/00063030-200115040-00002

Bibi, 2012, Trigger release liposome systems: local and remote controlled delivery?, J. Microencapsul., 29, 262, 10.3109/02652048.2011.646330

Bozzuto, 2015, Liposomes as nanomedical devices, Int. J. Nanomedicine, 10, 975, 10.2147/IJN.S68861

Campbell, 2002, Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors, Cancer Res., 62, 6831

Campbell, 2009, Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics, J. Pharm. Sci., 98, 411, 10.1002/jps.21458

Carlson, 1999, Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion, Am. J. Gastroenterol., 94, 1876, 10.1111/j.1572-0241.1999.01223.x

Chandrasekar, 2008, Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate, Ther. Clin. Risk Manag., 4, 1285, 10.2147/TCRM.S1554

Chang, 2012, Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy, Int. J. Nanomedicine, 7, 49, 10.2147/IJN.S26766

Chang, 2015, Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients, Cancer Chemother. Pharmacol., 75, 579, 10.1007/s00280-014-2671-x

Charron, 2015, Theranostic lipid nanoparticles for cancer medicine, Cancer Treat. Res., 166, 103, 10.1007/978-3-319-16555-4_5

Chrai, 2002, Liposomes (a review) part two: drug delivery systems, BioPharm, 17, 40

Clancy, 2013, Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection, Thorax, 68, 818, 10.1136/thoraxjnl-2012-202230

Coco, 2013, Drug delivery to inflamed colon by nanoparticles: comparison of different strategies, Int. J. Pharm., 440, 3, 10.1016/j.ijpharm.2012.07.017

Cole, 2015, Multifunctional nanoparticles for use in theranostic applications, Drug Deliv. Transl. Res., 5, 295, 10.1007/s13346-015-0218-2

Cullis, 1998, Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo, Adv. Drug Deliv. Rev., 32, 3, 10.1016/S0169-409X(97)00128-2

Dams, 2000, Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes, J. Pharmacol. Exp. Ther., 292, 1071

Dark, 2005, Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group, J. Clin. Oncol., 23, 1859, 10.1200/JCO.2005.02.028

Dempsey, 1996, C3d of complement as a molecular adjuvant: bridging innate and acquired immunity, Science, 271, 348, 10.1126/science.271.5247.348

Deshpande, 2013, Current trends in the use of liposomes for tumor targeting, Nanomedicine (Lond)., 8, 1509, 10.2217/nnm.13.118

Dicheva, 2013, Cationic thermosensitive liposomes: a novel dual targeted heat-triggered drug delivery approach for endothelial and tumor cells, Nano Lett., 13, 2324, 10.1021/nl3014154

Dicheva, 2014, Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes, J. Control. Release, 195, 37, 10.1016/j.jconrel.2014.07.058

Ding, 2006, Advanced drug delivery systems that target the vascular endothelium, Mol. Interv., 6, 98, 10.1124/mi.6.2.7

Felgner, 1987, Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. U.S.A., 84, 7413, 10.1073/pnas.84.21.7413

Ferrari, 2005, Nanovector therapeutics, Curr. Opin. Chem. Biol., 9, 343, 10.1016/j.cbpa.2005.06.001

Fetterly, 2008, Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel, Clin. Cancer Res., 14, 5856, 10.1158/1078-0432.CCR-08-1046

Gabizon, 1993, Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs, Pharm. Res., 10, 703, 10.1023/A:1018907715905

Gabizon, 1994, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res., 54, 987

Gabizon, 1991, Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin, Br. J. Cancer, 64, 1125, 10.1038/bjc.1991.476

Gabizon, 1982, Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice, Cancer Res., 42, 4734

Gabizon, 2003, In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice, Clin. Cancer Res., 9, 6551

Gabizon, 2002, Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models, J. Drug Target, 10, 539, 10.1080/1061186021000072447

Geng, 2014, Two cholesterol derivative-based PEGylated liposomes as drug delivery system, study on pharmacokinetics and drug delivery to retina, Nanotechnology, 25, 275103, 10.1088/0957-4484/25/27/275103

Giannella, 2015, High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial, Transplantation, 99, 848, 10.1097/TP.0000000000000393

Gross, 2013, Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes, Mol. Vis., 19, 54

Guo, 2003, Chemical approaches to triggerable lipid vesicles for drug and gene delivery, Acc. Chem. Res., 36, 335, 10.1021/ar9703241

Han, 2014, Development of a novel liposomal nanodelivery system for bioluminescence imaging and targeted drug delivery in ErbB2-overexpressing metastatic ovarian carcinoma, Int. J. Mol. Med., 34, 1225, 10.3892/ijmm.2014.1922

Hashizume, 2000, Openings between defective endothelial cells explain tumor vessel leakiness, Am. J. Pathol., 156, 1363, 10.1016/S0002-9440(10)65006-7

Hua, 2013, Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies, Front. Pharmacol., 4, 10.3389/fphar.2013.00127

Hua, 2013, Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition, Pain Physician, 16, E199, 10.36076/ppj.2013/16/E199

Hua, 2015, Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue, Nanomedicine, 11, 1117, 10.1016/j.nano.2015.02.018

Hua, 2013, The use of lipid-based nanocarriers for targeted pain therapies, Front. Pharmacol., 4, 10.3389/fphar.2013.00143

Immordino, 2006, Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential, Int. J. Nanomedicine, 1, 297

Ishida, 2005, Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes, J. Control. Release, 105, 305, 10.1016/j.jconrel.2005.04.003

Ishida, 2001a, Interactions of liposomes with cells in vitro and in vivo: opsonins and receptors, Curr. Drug Metab., 2, 397, 10.2174/1389200013338306

Ishida, 2006a, Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes, J. Control. Release, 115, 243, 10.1016/j.jconrel.2006.08.001

Ishida, 2006b, Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes, J. Control. Release, 112, 15, 10.1016/j.jconrel.2006.01.005

Ishida, 2001b, Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells, Biochim. Biophys. Acta, 1515, 144, 10.1016/S0005-2736(01)00409-6

Ishida, 2008, Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes, Int. J. Pharm., 354, 56, 10.1016/j.ijpharm.2007.11.005

Ishida, 2003, Accelerated clearance of a second injection of PEGylated liposomes in mice, Int. J. Pharm., 255, 167, 10.1016/S0378-5173(03)00085-1

Jaafar-Maalej, 2012, Lipid-based carriers: manufacturing and applications for pulmonary route, Expert Opin. Drug Deliv., 9, 1111, 10.1517/17425247.2012.702751

Jahn, 2015, Safety and efficacy of liposomal cytarabine in the treatment of neoplastic meningitis, Oncology, 89, 137, 10.1159/000380913

Kirpotin, 2006, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models, Cancer Res., 66, 6732, 10.1158/0008-5472.CAN-05-4199

Kirpotin, 1997, Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro, Biochem. Mosc., 36, 66, 10.1021/bi962148u

Klimuk, 1999, Contact hypersensitivity: a simple model for the characterization of disease-site targeting by liposomes, Biochim. Biophys. Acta, 1417, 191, 10.1016/S0005-2736(98)00261-2

Koning, 2003, Targeted drug delivery systems for the intracellular delivery of macromolecular drugs, Drug Discov. Today, 8, 482, 10.1016/S1359-6446(03)02699-0

Kono, 2001, Thermosensitive polymer-modified liposomes, Adv. Drug Deliv. Rev., 53, 307, 10.1016/S0169-409X(01)00204-6

Kraft, 2014, Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems, J. Pharm. Sci., 103, 29, 10.1002/jps.23773

Kunstfeld, 2003, Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a “humanized” SCID mouse model, J. Invest. Dermatol., 120, 476, 10.1046/j.1523-1747.2003.12057.x

Larsson, 2009, A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn, Glycobiology, 19, 756, 10.1093/glycob/cwp048

Laverman, 1999, Liposomes for scintigraphic detection of infection and inflammation, Adv. Drug Deliv. Rev., 37, 225, 10.1016/S0169-409X(98)00095-7

Laverman, 2001, Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology, Biochim. Biophys. Acta, 1526, 227, 10.1016/S0304-4165(01)00142-8

Löhr, 2012, Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial, Ann. Oncol., 23, 1214, 10.1093/annonc/mdr379

Lv, 2006, Toxicity of cationic lipids and cationic polymers in gene delivery, J. Control. Release, 114, 100, 10.1016/j.jconrel.2006.04.014

Lyass, 2000, Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma, Cancer, 89, 1037, 10.1002/1097-0142(20000901)89:51037::AID-CNCR133.0.CO;2-Z

Mangala, 2009, Liposomal siRNA for ovarian cancer, Methods Mol. Biol., 555, 29, 10.1007/978-1-60327-295-7_3

Maruyama, 2002, PEG-immunoliposome, Biosci. Rep., 22, 251, 10.1023/A:1020138622686

Metselaar, 2005, Liposomes in the treatment of inflammatory disorders, Expert Opin. Drug Deliv., 465, 76, 10.1517/17425247.2.3.465

Moghimi, 2006, Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production, FASEB J., 20, 2591, 10.1096/fj.06-6186fje

Moghimi, 2001, Capture of stealth nanoparticles by the body's defences, Crit. Rev. Ther. Drug Carrier Syst., 18, 527, 10.1615/CritRevTherDrugCarrierSyst.v18.i6.30

Moghimi, 2003, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog. Lipid Res., 42, 463, 10.1016/S0163-7827(03)00033-X

Monteiro, 2014, Liposomes in tissue engineering and regenerative medicine, J. R. Soc. Interface, 11, 20140459, 10.1098/rsif.2014.0459

Murday, 2009, Translational nanomedicine: status assessment and opportunities, Nanomedicine, 5, 251, 10.1016/j.nano.2009.06.001

Narang, 2013, Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems, J. Pharm. Sci., 102, 3867, 10.1002/jps.23691

Needham, 2000, A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model, Cancer Res., 60, 1197

Nehoff, 2014, Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect, Int. J. Nanomedicine, 9, 2539, 10.2147/IJN.S47129

Ning, 2007, Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma, Oncology (Williston Park), 21, 1503

Noble, 2004, Development of ligand-targeted liposomes for cancer therapy, Expert Opin. Ther. Targets, 8, 335, 10.1517/14728222.8.4.335

Northfelt, 1996, Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma, J. Clin. Pharmacol., 36, 55, 10.1002/j.1552-4604.1996.tb04152.x

Offner, 2004, Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B, Antimicrob. Agents Chemother., 48, 4808, 10.1128/AAC.48.12.4808-4812.2004

Oku, 1994, Long-circulating liposomes, Crit. Rev. Ther. Drug Carrier Syst., 11, 231

Olivier, 2014, Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease, Ann. Am. Thorac. Soc., 11, 30, 10.1513/AnnalsATS.201307-231OC

Ozpolat, 2003, Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers, J. Pharm. Pharm. Sci., 6, 292

Park, 2002, Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery, Clin. Cancer Res., 8, 1172

Peterson, 2002, A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease, Am. J. Gastroenterol., 97, 1755, 10.1111/j.1572-0241.2002.05837.x

Ponce, 2006, Hyperthermia mediated liposomal drug delivery, Int. J. Hyperthermia, 22, 205, 10.1080/02656730600582956

Poste, 1976, Lipid vesicles as carriers for introducing biologically active materials into cells, Methods Cell Biol., 14, 33, 10.1016/S0091-679X(08)60468-9

Puri, 2009, Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic, Crit. Rev. Ther. Drug Carrier Syst., 26, 523, 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10

Rahman, 2007, Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation, Int. J. Nanomedicine, 2, 567

Ran, 2002, Increased exposure of anionic phospholipids on the surface of tumor blood vessels, Cancer Res., 62, 6132

Riehemann, 2009, Nanomedicine–challenge and perspectives, Angew. Chem. Int. Ed Engl., 48, 872, 10.1002/anie.200802585

Rip, 2014, Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats, J. Drug Target., 22, 460, 10.3109/1061186X.2014.888070

Sapra, 2003, Ligand-targeted liposomal anticancer drugs, Prog. Lipid Res., 42, 439, 10.1016/S0163-7827(03)00032-8

Sawant, 2012, Challenges in development of targeted liposomal therapeutics, AAPS J., 14, 303, 10.1208/s12248-012-9330-0

Schmitt, 2012, Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors, Ann. Hematol., 91, 391, 10.1007/s00277-011-1308-y

Seiden, 2004, A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer, Gynecol. Oncol., 93, 229, 10.1016/j.ygyno.2003.12.037

Senior, 1987, Fate and behavior of liposomes in vivo: a review of controlling factors, Crit. Rev. Ther. Drug Carrier Syst., 3, 123

Storm, 1998, Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system, Clin. Cancer Res., 4, 111

Suenaga, 2015, Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study, Drug Des. Devel. Ther., 9, 3099, 10.2147/DDDT.S85567

Szebeni, 2005, Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity, Toxicology, 216, 106, 10.1016/j.tox.2005.07.023

Szebeni, 2007, Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles, J. Liposome Res., 17, 107, 10.1080/08982100701375118

Szebeni, 2009, Adverse immune effects of liposomes: complement activation, immunogenicity and immune suppression, Harnessing Biomaterials for Nanomedicine: Preparation, Toxicity and Applications, 1

Szebeni, 1999, Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody, Circulation, 99, 2302, 10.1161/01.CIR.99.17.2302

Szebeni, 2009, Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions, J. Liposome Res., 19, 85, 10.1080/08982100902792855

Teli, 2010, Nanotechnology and nanomedicine: going small means aiming big, Curr. Pharm. Des., 16, 1882, 10.2174/138161210791208992

Tinkle, 2014, Nanomedicines: addressing the scientific and regulatory gap, Ann. N.Y. Acad. Sci., 1313, 35, 10.1111/nyas.12403

Tirosh, 2009, Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa, Mol. Pharm., 6, 1083, 10.1021/mp9000926

Torchilin, 1994, Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents, Immunomethods, 4, 244, 10.1006/immu.1994.1027

Torchilin, 1992, Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium, FASEB J., 6, 2716, 10.1096/fasebj.6.9.1612296

Ulrich, 2002, Biophysical aspects of using liposomes as delivery vehicles, Biosci. Rep., 22, 129, 10.1023/A:1020178304031

Vingerhoeds, 1994, Immunoliposomes in vivo, Immunomethods, 4, 259, 10.1006/immu.1994.1028

Wang, 2015, Are PEGylated liposomes better than conventional liposomes? A special case for vincristine, Drug Deliv., 29, 1, 10.3109/10717544.2015.1027015

Webb, 1998, Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine, Biomembranes, 1372, 272, 10.1016/S0005-2736(98)00077-7

Wetzler, 2013, Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia, Clin. Lymphoma Myeloma Leuk., 13, 430, 10.1016/j.clml.2013.03.015

Willis, 1998, Ligand-targeted liposomes, Adv. Drug Deliv. Rev., 29, 249, 10.1016/S0169-409X(97)00083-5

Wu, 2007, Vascular targeting of doxorubicin using cationic liposomes, Int. J. Pharm., 337, 329, 10.1016/j.ijpharm.2007.01.003

Yarmolenko, 2010, Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours, Int. J. Hyperthermia, 26, 485, 10.3109/02656731003789284

Zamboni, 2009, Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies, Clin. Cancer Res., 15, 1466, 10.1158/1078-0432.CCR-08-1405

Zhang, 2011, Drug delivery systems for differential release in combination therapy, Expert Opin. Drug Deliv., 8, 171, 10.1517/17425247.2011.547470

Zhang, 2005, Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation, Eur. J. Pharm. Biopharm., 59, 177, 10.1016/j.ejpb.2004.06.009

Zhang, 2004, Development and characterization of a novel liposome-based formulation of SN-38, Int. J. Pharm., 270, 93, 10.1016/j.ijpharm.2003.10.015

Zhang, 2008, Nanoparticles in medicine: therapeutic applications and developments, Clin. Pharmacol. Ther., 83, 761, 10.1038/sj.clpt.6100400

Zou, 1994, Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties, Cancer Res., 54, 1479